5 FDA Decisions to Watch in the Second Half of 2024 6/24/2024

FDA Action Alert: Merck, Verona, AbbVie and Rocket 6/24/2024

Each second of our lives, cells in our body grow and divide to ensure we stay healthy. However, this process has a dark side: if cell growth and divisions become excessive, that may cause cancer. To keep a safe balance, our cells are equipped with several molecular mechanisms to limit their own growth and division.

EMBL Hamburg's Wilmanns Group, in collaboration with research groups from the Center for Experimental Medicine Institute of Tumor Biology and the Martini Clinic at the University Medical Center Hamburg-Eppendorf (UKE), as well as the Leibniz Institute on Aging - Fritz Lipmann Institute, has revealed a new mechanism

Expanded Approval of Sarepta’s Elevidys Is Progress, But More Needed for DMD Patients 6/21/2024

Zealand Deepens Weight-Loss Portfolio With Strong Phase Ib Data for GLP-1 Alternative 6/21/2024

Jazz’s Tremor Drug Candidate Flops in Phase II Study, Misses Primary Endpoint 6/21/2024

Vertex Finally Reaches Pricing Deal with England’s NHS for Cystic Fibrosis Drug 6/21/2024

Vanda Turns Down Cycle, Future Pak Offers as Proposals ‘Undervalue’ Company 6/21/2024

Tectonic Completes Reverse Merger With Avrobio, Starts Trading on Nasdaq 6/21/2024

Sarepta Wins Full Approval and Label Expansion for DMD Gene Therapy 6/21/2024

A class of drugs already on the market to lower blood pressure appears to reduce adults' risk of developing epilepsy, Stanford Medicine researchers and their colleagues have discovered. The finding comes out of an analysis of the medical records of more than 2 million Americans taking blood pressure medications.

The study, published June 17 in JAMA Neurology, suggests that the drugs, called angiotensin receptor blockers, could prevent epilepsy in people at highest risk of the disease, including older adults who have had strokes.

Lilly Takes More Legal Actions Over Compounded Tirzepatide, Warns About Counterfeits 6/20/2024

Gilead’s Twice-Yearly Shot Shows 100% Efficacy in Phase III HIV Prevention Trial in Women 6/20/2024

PTC Reports Positive Phase II Huntington’s Data, FDA Lifts Partial Clinical Hold 6/20/2024

Challenging Research Models to Improve Health Equity 6/20/2024

Experimental Parkinson’s Treatment Elicits Antibodies Against Toxic Protein in Phase I 6/20/2024

BioSpace at #DIA2024: Workforce Trends, Trial Design, Peter Marks & Recap 6/20/2024

Executives Share Top Tips for a Successful Career Journey 6/20/2024

Better Collaboration: 7 Tips for Effective Workplace Communication 6/20/2024

FTC Supports PTO Push for Patent Settlement Scrutiny, Better Antitrust Oversight 6/20/2024